{"schema_version":"1","generated_at":"2026-11-08T01:31:10.294Z","data_as_of":"2026-11-07","url":"https://www.findmykol.com/kol/michael-schweizer","json_url":"https://www.findmykol.com/kol/michael-schweizer/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"michael-schweizer","name":"Michael Schweizer","credential":"MD","title":"Professor, Division of Hematology and Oncology","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Genitourinary","therapeutic_areas":["Genitourinary","Breast"],"institution":"University of Washington","institution_url":"https://www.findmykol.com/institution/university-of-washington","city":"Seattle","state":"WA","region":{"label":"West","url":"https://www.findmykol.com/region/west"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1942463450","orcid":"0000-0002-5510-0661","openalex":"A5014339741"},"summary":"Michael Schweizer is Professor, Division of Hematology and Oncology at University of Washington. OpenAlex indexes 290 publications with 7,258 citations (h-index 43); ClinicalTrials.gov lists 21 registered studies with this person as an investigator.","overview":{"text":"Michael Schweizer, M.D., is Professor, Division of Hematology and Oncology at University of Washington. The public record shows 290 publications with 7,258 citations (h-index 43), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 5 companies, 1 NIH-funded awards (2024–2026).","bullets":["Most recent indexed publication: 2026 · Clinical cancer research","Top research focus: Prostate Cancer Treatment and Research","21 registered trials on ClinicalTrials.gov","Open Payments reporting from 5 companies"],"generated_at":"2026-11-07"},"focus":{"indications":[{"label":"Prostate Cancer","therapeutic_area":"Oncology","trials":18,"topics":0,"strength":55},{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":4},{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":4},{"label":"Bladder / Urothelial Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":4},{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":4},{"label":"Carcinoma, Small Cell","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"MDS / MPN","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Primary Myelofibrosis","therapeutic_area":"Hematology","trials":1,"topics":0,"strength":3},{"label":"Microsatellite Instability","therapeutic_area":"Epidemiology","trials":1,"topics":0,"strength":3},{"label":"Carcinoma, Neuroendocrine","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Melanoma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Kidney Cancer / RCC","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Sarcoma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"COVID-19","therapeutic_area":"Infectious Disease","trials":0,"topics":0,"strength":1},{"label":"Colorectal Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1}],"research_topics":["Prostate Cancer Treatment and Research","Prostate Cancer Diagnosis and Treatment","Cancer Genomics and Diagnostics","Chromatin Remodeling and Cancer","Advanced Breast Cancer Therapies"],"drugs_studied":{"total":6,"shown":3,"withheld":3,"rows":[{"name":"Enzalutamide","trials":1,"payments":0,"publications":3,"mentions":4},{"name":"Jevtana","generic":"Cabazitaxel","trials":0,"payments":2,"publications":1,"mentions":3},{"name":"Lynparza","generic":"Olaparib","trials":0,"payments":1,"publications":1,"mentions":2}]},"works_with":{"total":14,"shown":3,"withheld":11,"rows":[{"name":"University of Washington","trials":10,"payments":0,"mentions":10},{"name":"Pfizer Inc.","trials":0,"payments":8,"mentions":8},{"name":"Fred Hutchinson Cancer Center","trials":4,"payments":0,"mentions":4}]}},"scholarship":{"works_count":290,"cited_by_count":7258,"h_index":43,"i10_index":105,"pubmed_count":31,"latest_activity_year":2026,"source":"works"},"trials":{"count":21,"shown":3,"withheld":18,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07852195","title":"Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer","phase":"PHASE2/PHASE3","status":"NOT_YET_RECRUITING","role":"Investigator","sponsor":"ECOG-ACRIN Cancer Research Group","source_url":"https://clinicaltrials.gov/study/NCT07852195","trial_url":"https://www.findmykol.com/trial/NCT07852195"},{"nct":"NCT07698535","title":"Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"University of Washington","source_url":"https://clinicaltrials.gov/study/NCT07698535","trial_url":"https://www.findmykol.com/trial/NCT07698535"},{"nct":"NCT07592910","title":"A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy","phase":"PHASE2","status":"NOT_YET_RECRUITING","role":"Investigator","sponsor":"Prostate Cancer Clinical Trials Consortium","source_url":"https://clinicaltrials.gov/study/NCT07592910","trial_url":"https://www.findmykol.com/trial/NCT07592910"}],"source":"trials"},"payments":{"company_count":5,"program_years":{"first":2021,"last":2025},"rows_total":8,"shown":3,"withheld":5,"rows":[{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":4050,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1942463450"},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":1800,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1942463450"},{"payer":"PFIZER INC.","program_year":2024,"amount_usd":2477.09,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1942463450"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1942463450","source":"payments"},"prescribing":{"data_year":2024,"areas_total":4,"areas_shown":3,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":45.1,"classes_total":2,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":38.4,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":31},{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":6.7,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":15}]},{"area":"Cancer & immunology","share_pct":43,"classes_total":3,"classes":[{"class":"Cytochrome P450 17A1 Inhibitor","setting":"prescribed","share_pct":31.3,"drugs":[{"name":"Abiraterone Acetate","share_pct":100}],"max_beneficiaries":23},{"class":"Anti-androgens","setting":"prescribed","share_pct":6.7,"drugs":[{"name":"Nubeqa","share_pct":100}],"max_beneficiaries":null}]},{"area":"Sensory organs","share_pct":6.7,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":6.7,"drugs":[{"name":"Dexamethasone","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":86.2,"facility_pct":13.8},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2024,"last":2026},"rows_total":3,"shown":3,"withheld":0,"rows":[{"project":"R37CA286450","title":"Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy","fiscal_year":2026,"amount_usd":667980,"organization":"FRED HUTCHINSON CANCER CENTER","source_url":"https://reporter.nih.gov/quickSearch/R37CA286450"},{"project":"R37CA286450","title":"Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy","fiscal_year":2025,"amount_usd":668068,"organization":"FRED HUTCHINSON CANCER CENTER","source_url":"https://reporter.nih.gov/quickSearch/R37CA286450"},{"project":"R37CA286450","title":"Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy","fiscal_year":2024,"amount_usd":720165,"organization":"FRED HUTCHINSON CANCER CENTER","source_url":"https://reporter.nih.gov/quickSearch/R37CA286450"}],"source":"grants"},"congress":{"count":107,"years":{"first":2010,"last":2026},"societies":["AACR","ASCO","ASTRO","AUA","ESMO"],"shown":3,"withheld":104,"rows":[{"title":"Abstract 3826: Systematic assessment of histomorphologic and immunohistochemical features in metastatic castration-resistant prostate cancer biopsies","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-3826","source_url":"https://doi.org/10.1158/1538-7445.am2026-3826","status":"verified"},{"title":"Abstract LB006: Prostate cancer phenotypes determined from circulating tumor DNA associate with outcomes to 177Lu-PSMA-617 therapy","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"late_breaking_abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-lb006","source_url":"https://doi.org/10.1158/1538-7445.am2026-lb006","status":"verified"},{"title":"Efficacy and safety of mevrometostat (M) in combination with enzalutamide (E) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from a phase 1 study.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.7_suppl.195","source_url":"https://doi.org/10.1200/jco.2026.44.7_suppl.195","status":"verified"}],"source":"congress"},"publications":{"total":31,"shown":5,"withheld":26,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"SPEN Inactivation Drives Resistance to Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42594031/","status":"verified"},{"title":"Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression Reflect Prostate Cancer Phenotypes in Metastatic Disease.","year":2026,"journal":"The Prostate","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42860034/","status":"verified"},{"title":"Image-based Detection of Mismatch Repair Deficiency in Prostate Cancer Using Transfer Learning.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42808876/","status":"verified"},{"title":"Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.","year":2026,"journal":"Prostate cancer and prostatic diseases","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42697914/","status":"verified"},{"title":"Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.","year":2026,"journal":"Molecular cancer research : MCR","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42189191/","status":"verified"}],"source":"publications"},"presence":{"owned_accounts":{"total":3,"shown":3,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/michael-schweizer-md","status":"verified"},{"platform":"linkedin","url":"https://www.linkedin.com/in/michael-schweizer-475a64272","status":"verified"},{"platform":"researchgate","url":"https://www.researchgate.net/profile/Michael-Schweizer-3","status":"verified"}]},"mentions":{"total":5,"shown":3,"rows":[{"url":"https://podcasts.apple.com/us/podcast/high-dose-testosterone-bat-for-prostate-cancer-with-dr/id1609860250?i=1000777797507&uo=4","platform":"apple_podcasts","status":"provisional"},{"url":"https://hemonc.uw.edu/people/michael-schweizer","platform":"other","status":"verified"},{"url":"https://www.urotoday.com/video-lectures/asco-2024/video-2/4130-targeting-ezh2-in-prostate-cancer-the-role-of-mevrometostat-in-preventing-neuroendocrine-differentiation-michael-schweizer.html","platform":"other","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":3,"shown":3,"rows":[{"value":"MD, Temple University School of Medicine","source_url":"https://hemonc.uw.edu/people/michael-schweizer","status":"verified","collected_at":"2026-11-07"},{"value":"Medical Oncology, American Board of Internal Medicine","source_url":"https://hemonc.uw.edu/people/michael-schweizer","status":"verified","collected_at":"2026-11-07"},{"value":"Internal Medicine, American Board of Internal Medicine","source_url":"https://hemonc.uw.edu/people/michael-schweizer","status":"verified","collected_at":"2026-11-07"}]},"roles":{"total":2,"shown":2,"rows":[{"value":"Co-Leader of SPORE Project 4: Clinical Development of Therapeutic Strategies Targeting","source_url":"https://www.fredhutch.org/en/research/institutes-networks-ircs/pnw-prostate-spore/team.html","status":"provisional","collected_at":"2026-11-07"},{"value":"Clinical Research Director, GU/Prostate, Fred Hutch and UW Medicine","source_url":"https://hemonc.uw.edu/people/michael-schweizer","status":"verified","collected_at":"2026-11-07"}]},"secondary_affiliations":{"total":2,"shown":2,"rows":[{"value":"Fred Hutchinson Cancer Research Center","source_url":"https://orcid.org/0000-0002-5510-0661","status":"verified","collected_at":"2026-11-07"},{"value":"Fred Hutch Cancer Center","source_url":"https://hemonc.uw.edu/people/michael-schweizer","status":"verified","collected_at":"2026-11-07"}]},"media":{"total":3,"shown":3,"rows":[{"value":"UroToday video: Targeting EZH2 in Prostate Cancer, ASCO 2024 (Michael Schweizer)","source_url":"https://www.urotoday.com/video-lectures/asco-2024/video-2/4130-targeting-ezh2-in-prostate-cancer-the-role-of-mevrometostat-in-preventing-neuroendocrine-differentiation-michael-schweizer.html","status":"provisional","collected_at":"2026-11-07"},{"value":"Dr. Geo Prostate Podcast: High-Dose Testosterone (BAT) for Prostate Cancer with Dr. Michael Schweizer","source_url":"https://open.spotify.com/episode/3MvOzH3mAcUB3lsYelzdKn","status":"provisional","collected_at":"2026-11-07"},{"value":"OncLive video: Dr. Schweizer on the Results of the HERO Trial in Prostate Cancer","source_url":"https://www.onclive.com/view/dr-schweizer-on-the-results-of-the-hero-trial-in-prostate-cancer","status":"provisional","collected_at":"2026-11-07"}]}},"similar":[{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Connie Celum","slug":"connie-celum","institution":"University of Washington","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/connie-celum","json_url":"https://www.findmykol.com/kol/connie-celum/profile.json"},{"name":"Helen Chu","slug":"helen-chu","institution":"University of Washington","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/helen-chu","json_url":"https://www.findmykol.com/kol/helen-chu/profile.json"},{"name":"Bryan Kestenbaum","slug":"bryan-kestenbaum","institution":"University of Washington","specialty":"Nephrology","url":"https://www.findmykol.com/kol/bryan-kestenbaum","json_url":"https://www.findmykol.com/kol/bryan-kestenbaum/profile.json"},{"name":"Howard Scher","slug":"howard-scher","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/howard-scher","json_url":"https://www.findmykol.com/kol/howard-scher/profile.json"},{"name":"Toni Choueiri","slug":"toni-choueiri","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/toni-choueiri","json_url":"https://www.findmykol.com/kol/toni-choueiri/profile.json"},{"name":"Robert Motzer","slug":"robert-motzer","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/robert-motzer","json_url":"https://www.findmykol.com/kol/robert-motzer/profile.json"},{"name":"Fred Saad","slug":"fred-saad","institution":"Centre hospitalier de l'Université de Montréal (CHUM)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/fred-saad","json_url":"https://www.findmykol.com/kol/fred-saad/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":18,"payments":5,"congress":104,"publications":26}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-07"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-07"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-11-07"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-11-07"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-11-07"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-11-07"}},"methodology_url":"https://www.findmykol.com/about#methodology"}